Attorneys representing individuals who claim have suffered severe tendon damage as a result of taking the prescription antibiotic Levaquin are gearing up for the first Levaquin trial. A status conference will take place today for Levaquin lawyers to discuss status of Levaquin lawsuits pending in federal court.
The first of six bellwether cases is expect to begin in the early part of November and today’s meeting will be a good opportunity for Levaquin attorneys and the Court to review the status of the litigation and address outstanding motions.
There are currently over 750 Levaquin lawsuits pending in federal court, with an additional 573 cases pending in state court, most of which have been filed in New Jersey.
Federal Levaquin lawsuits have been centralized to a multi-district litigation (MDL) in the U.S. District Court of Minnesota under Judge John R. Tunheim.
According to the agenda today’s status conference will serve as an opportunity for attorneys and the Court to schedule the second Levaquin bellwether trial.
The bellwether trials will give attorneys representing both sides a good indication of how juries will respond to similar evidence and injuries that are present throughout many Levaquin lawsuits, and potentially lay the groundwork for a future settlement.
Levaquin is a popular antibiotic medication that is manufactured and distributed by pharmaceutical giant Johnson & Johnson. Levaquin can be prescribed to treat a wide variety of ailments but is most commonly used to treat sinus, lung, and urinary infections.
Due to a high number of adverse tendon related events reported to the FDA by Levaquin users, the agency required the medication to include the infamous "black box" warning for tendinitis and tendon injuries, including tendon rupture, to the drug’s label.